Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

56.00 -2.59 (-4.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 576,369
Open 58.25
Bid (Size) 52.65 (100)
Ask (Size) 62.45 (100)
Prev. Close 58.59
Today's Range 55.93 - 58.35
52wk Range 28.19 - 63.95
Shares Outstanding 63,562,303
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Xenon (XENE) Q1 2026 Earnings Transcript ↗
Xenon (XENE) Q1 2026 Earnings Transcript 
Via The Motley Fool
Xenon Pharmaceuticals (NASDAQ:XENE) Reports Mixed Q1 Results as Azetukalner Nears FDA Submission ↗
Via Chartmill

Performance

YTD
+25.9%
+25.9%
1 Month
-2.9%
-2.9%
3 Month
+38.6%
+38.6%
6 Month
+46.2%
+46.2%
1 Year
+58.5%
+58.5%

More News

Read More
News headline image
Xenon Reports Q1 2026 Financial Results and Provides Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Breakout Setup Combines 9/10 Technical Strength with 9/10 Consolidation Quality ↗
Via Chartmill
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Report Q1 2026 Financial Results on May 7, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at Upcoming Investor Conferences
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
Via Finterra
Topics ETFs Intellectual Property
News headline image
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’ ↗
Via Stocktwits
News headline image
Xenon Pharmaceuticals Announces Proposed Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Xenon Pharmaceuticals Inc. - Common Shares publicly traded?
Yes, Xenon Pharmaceuticals Inc. - Common Shares is publicly traded.
What exchange does Xenon Pharmaceuticals Inc. - Common Shares trade on?
Xenon Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares?
The ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares is XENE on the Nasdaq Stock Market
What is the current price of Xenon Pharmaceuticals Inc. - Common Shares?
The current price of Xenon Pharmaceuticals Inc. - Common Shares is 56.00
When was Xenon Pharmaceuticals Inc. - Common Shares last traded?
The last trade of Xenon Pharmaceuticals Inc. - Common Shares was at 05/07/26 04:00 PM ET
What is the market capitalization of Xenon Pharmaceuticals Inc. - Common Shares?
The market capitalization of Xenon Pharmaceuticals Inc. - Common Shares is 3.56B
How many shares of Xenon Pharmaceuticals Inc. - Common Shares are outstanding?
Xenon Pharmaceuticals Inc. - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.